Navigation Links
SLE in Medical Technology

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

...at emerged in the serologically active subgroup of sle patients at Week 52 in our Phase 2 trial," said Da...significance. BENLYSTA also significantly reduced sle disease activity versus placebo based on a number ...n collaboration with GSK and leading international sle experts, and the program is being conducted under ...

Lupus Foundation of America Fosters the Next Generation of Lupus Researchers by Awarding Gina M. Finzi Memorial Student Summer Fellowships to Five Students

... Tarak Trivedi, The University of Chicago (Chicago, IL) "Analysis of sle Clinical Characteristics Using sle Susceptibility Genes" The Foundation's national research program, Bri...

Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference

... 2010, and we believe it could become the first new drug approved by the FDA for the treatment of lupus in 50 years," said Mr. Watkins. "Patients with sle need new treatment options; we hope to be able to help meet that need with LymphoStat-B." Key goals for LymphoStat-B in 2009: R...

Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus

...lled trials evaluating the efficacy and safety of epratuzumab for the treatment of severe BILAG A and/or moderate BILAG B in two or more organ systems sle flare, respectively. Both trials terminated early due to interruptions in medication supply. Among both trials, 90 patients were randomized to receive...

Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial

...ort of a potential Biologics License Application (BLA). HGS designed the belimumab Phase 3 program in collaboration with GSK and leading international sle experts. "The belimumab clinical investigators have done a tremendous job in completing the randomization and initial dosing of BLISS-52 and BLISS-7...

Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus

...uman monoclonal antibody targeting interferon-alpha. Published data indicate that levels of interferon-alpha are elevated in many patients with active sle and other autoimmune disorders, and may be associated with disease activity. Preclinical data from animal models suggest that MEDI-545 may suppress th...

Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus

...play an important role in the treatment of SLE." sle is a chronic, life-threatening autoimmune disease....cally active SLE, we saw significant reductions in sle disease activity versus placebo based on multiple ...epresent a significant advance in the treatment of sle if Phase 2 results are confirmed in the Phase 3 tr...

Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives

...tific meetings at earlier time points, including a significant reduction in sle disease activity as measured by the response rate chosen as the primary eff... a protocol design informed by prior randomized data. Today's therapy for sle patients involves a variety of immunosuppressive and cytotoxic agents, with...

Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus

...al of Rituxan (rituximab) for the treatment of lupus. The study did not meet its primary or secondary endpoints of clinically reducing the severity of sle (systemic lupus erythematosus) in people with moderate disease. The findings are initial results from a Phase II/III study conducted by Genentech,...

Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials

...he results of previous studies suggest that belimumab significantly reduced sle disease activity in serologically active patients," said Professor Sandra V...oStat-B Phase 3 program in collaboration with GSK and leading international sle experts. "A total of nearly 1700 patients worldwide will be enrolled and ...

Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus

... observed for LymphoStat-B in serologically active sle patients at 52 weeks appears to be sustained throu... with active SLE, we saw significant reductions in sle disease activity versus placebo as measured by the...rsus placebo in patients with serologically active sle across multiple clinical measures, exhibited clini...

Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus

...TLRs 7, 8 and 9 and inhibit disease development in sle and other autoimmune disorders. CPG 52364 has been...medical need." CPG 52364's Mechanism of Action in sle The defining characteristic of sle is the production of autoantibodies, abnormal anti...

La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial

...0 (US) or (617) 801-6888 (International). The passcode for the replay is 33112152. These data will be presented at the 8th International Congress on sle in Shanghai in May 2007. Phase 3 Study Design The Phase 3 study is designed to assess the ability of Riquent treatment to prevent or delay the tim...

Positive Clinical Data for TASQ - Active Biotech's Novel Treatment of Prostate Cancer

...n being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for sle and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics. Ac...

Active Biotech's I-3D Micro-dosing Clinical Trial Concluded

...n being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for sle and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics. Ac...

La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent Lupus Phase 3 Trial

...from that seen in previous studies where 100 mg of Riquent was the treatment dose. These data will be presented at the 8th International Congress on sle in Shanghai in May 2007. Phase 3 Study Design The Phase 3 study is designed to assess the ability of Riquent treatment to prevent or delay the tim...

Laquinimod, a Novel Oral Compound, Showed Significant Reduction in Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)

... being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for sle and RhuDex(R) for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics Interna...

ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia

...s such as systemic lupus erythematosus (SLE). Current data indicates that levels of BLyS and APRIL are elevated in patients with rheumatoid arthritis, sle and B-cell malignancies. Atacicept has been shown to affect several stages of B-cell development and may inhibit the survival of cells responsible for...

Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus

...lyn. "At Week 52, we saw significant reductions in sle disease activity as measured by the SELENA SLEDAI ...ation of LymphoStat-B as a potential treatment for sle in the Phase 3 trials that are now underway," she ...ndard of care. A total of 449 patients with active sle were randomized to receive one of three different ...

New Positive Pre-clinical Data for Active Biotech's RA Project I-3D

... being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for sle and RhuDex® for RA. In addition, the preclinical development of the I-3D project is conducted in cooperation with Chelsea Therapeutics Internation...

Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation

...clinical development of 57-57 for the treatment of sle and show the possibility to reduce the use of ster...Sven Andréasson President & CEO About sle and 57-57 Systematic Lupus Erythematosus (SLE) is ...in the US and Europe. The market potential for the sle indication is estimated at approximately USD 6 bil...

Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis

...on. Aspreva estimates that there are about 600,000 diagnosed lupus nephritis patients worldwide. There have been no new approved treatment options for sle or lupus nephritis in the United States in over forty years. Current induction treatments involve the off-label use of existing cancer drugs such as c...

Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease

...al thrombosis) in patients with autoimmune diseases such as systemic lupus erythematosus (SLE) and anti-phospholipid syndrome. The study looked at 113 sle patients (94 with secondary anti-phospholipid syndrome and 19 without) and concluded the measurement of anti-AtherOx is significantly better than conv...
Other Tags
(Date:10/15/2014)... of Life, is a non-traditional biophysics textbook and it ... is a journey of discovery into biological systems and ... biological regulation. It is about how our genes make ... the billions of cells in an organism. It quantifies ... principles, which can be found on both large and ...
(Date:10/15/2014)... and to an unexpected extent. The outbreak does not ... virus shows a new disease dynamic in regions, where ... the German National Academy of Sciences Leopoldina, acatech – ... Union of the German Academies of Sciences and Humanities ... , In the statement the academies call for the ...
(Date:10/15/2014)... , Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market releases photos ... in Times Square on Monday October 13 th . ... David Tunnel and angel investor Mr. Chad A. ... , CEO of NXT-ID thanked his investors and employees "for their ...
Breaking Biology News(10 mins):New book about life as seen from physics 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
(Date:10/25/2014)... -- Arriving home safe and sound is one of the ... sure that costumes and goody bags have reflective strips that ... medicine doctor at Meadowlands Hospital Medical Center in Secaucus, N.J. ... should be flame-resistant, Davis said. He offers these others ... it on a small area of skin first to ensure ...
(Date:10/25/2014)... October 25, 2014 The ... which verifies IT-accessibility for disabled users by disabled ... logo to Mackin Educational Resources of Burnsville, ... management system and to the Minnesota Alliance for ... "Own Best Medicine" website. Both organizations ...
(Date:10/25/2014)... York, New York (PRWEB) October 25, 2014 ... transvaginal mesh lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed ... litigation underway in U.S. District Court, Southern District ... for Summary Judgment on Punitive Damages in a ... plaintiffs. In a ruling issued on October 21st, ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, 2014 (HealthDay ... herpes simplex -- might increase the risk of Alzheimer,s disease, ... a carrier of certain antibodies to the virus can double ... "The identification of a treatable cause [herpes simplex] of the ... Dr. Hugo Lovheim, an associate professor in the department of ...
(Date:10/25/2014)... Current osteoporosis screening guidelines and tools fail to ... osteoporosis-related fractures, a new study says. "If ... that help us accurately predict who will suffer ... these at-risk people for preventive measures," study author ... division of general internal medicine and health services ...
Breaking Medicine News(10 mins):Health News:Tips for Safe Trick-or-Treating 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2
Other Contents